My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

59.44 +0.18 (+0.30%)

Streaming Delayed Price Updated: 11:58 AM EST, Feb 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

44 45 Next >

GSK's Arexvy Gets the Green Light in Europe: First-Ever RSV Vaccine in Europe for Older Adults ↗

June 07, 2023

The European Commission has approved GSK plc's (NYSE:

Via Benzinga

June 2023 Stock Considerations ↗

June 07, 2023

With a new trading month already in full swing it is time, once again, to highlight some of my potential stock purchases.

Via Talk Markets

SEC Accuses Binance & Coinbase Of Acting As Unregistered Broker, Binance Takes Biggest Hit As $300M In Crypto Positions Liquidated In 24 Hours, JPMorgan Clarifies CEO Jamie Dimon Not Running For Presidency: Today's Top Stories ↗

June 06, 2023

Benzinga

Via Benzinga

FDA Prioritizes GSK's Breakthrough Drug Jemperli for Endometrial Cancer Treatment, a First in Decades ↗

June 06, 2023

Via Benzinga

Peering Into GSK's Recent Short Interest ↗

May 19, 2023

Via Benzinga

GSK Announces the COiMMUNITY Initiative to Help Achieve Higher Adult Vaccination Rates in the US

June 01, 2023

From GSK plc

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 25, 2023

Via Benzinga

WHO Recommends New COVID Booster Shots To Target XBB Variants, Despite Slower Uptake ↗

May 19, 2023

An advisory group for the World Health Organization said the current crop of shots should be updated to target the currently dominant XBB strains for the

Via Benzinga

BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition

May 16, 2023

From BELLUS Health Inc.

Via Business Wire

Could Latecomer Moderna Match Big Pharma Rivals in RSV? ↗

May 16, 2023

RSV is a key part of Moderna's respiratory vaccine business.

Via The Motley Fool

A Bitter Pill to Swallow: Teva's $235M Challenge to GSK Dismissed by Supreme Court ↗

May 15, 2023

The U.S.

Via Benzinga

3 Personalized Medicine Stocks to Buy for Long-Time Returns ↗

May 15, 2023

Personalized medicine is the future of medicine. Here are three personalized medicine stocks to invest in so you don't miss out.

Via InvestorPlace

GSK's Meningitis Vaccine Candidate: Crushing Clinical Trials or Just Playing Catch-up with Bexsero and Menveo? ↗

May 12, 2023

GSK plc (NYSE: GSK) presented preliminary results from the phase 3 trial of imm

Via Benzinga

Sanofi, AstraZeneca Release Real-World Data For Respiratory Syncytial Virus Antibody ↗

May 12, 2023

The race to tap the respiratory syncytial virus (RSV) this season intensifies as Sanofi SA (NASDAQ: SNY) and AstraZeneca Plc (NASDAQ: AZN) have

Via Benzinga

GSK Trims Stake On Consumer Business Spin Off, Raises £804M ↗

May 12, 2023

GSK Plc (NYSE: GSK) sold 240 mi

Via Benzinga

Sanofi Says Its RSV Shot Significantly Cut Hospitalization Risk In Newborns ↗

May 12, 2023

The monoclonal antibody shot significantly reduced the risk of hospitalization in babies.

Via Investor's Business Daily

SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress

May 11, 2023

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

The FDA Just Approved an RSV Vaccine -- and It Isn't From Moderna or Pfizer ↗

May 11, 2023

RSV could be the next big battleground for big pharma -- but it could soon become crowded.

Via The Motley Fool

Dividend Income Update April 2023 ↗

May 11, 2023

With May already underway it is time for all dividend income investors to look back at the previous month and see how much passive dividend income their portfolios generated.

Via Talk Markets

ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results

May 08, 2023

Commercial-state biotechnology company ImmunoGen Inc. (NASDAQ: IMGN) shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug

Via MarketBeat

WHO Ends Global Emergency Status for COVID-19 3 Years After Declaration, CDC Director Resigns ↗

May 08, 2023

The World Health Organization ended the global emergency

Via Benzinga

GSK: Add This Cheap Chip Play To Your Portfolio ↗

May 06, 2023

GSK pays a decent quarterly dividend. The latest declared dividend is $0.35 per share, giving GSK a yield of 3.85%.

Via Talk Markets

International Healthcare Week returns to showcase Hong Kong's strengths in healthcare innovation and investment

May 04, 2023

From HKTDC

Via ACN Newswire

A Shot of Success: GSK's Arexvy Wins FDA Approval, Pioneering RSV Prevention for Older Adults in Multi-Billion Dollar Market ↗

May 03, 2023

The FDA has approved GSK Plc's (NYSE: GSK) Arexvy (respiratory syncytial virus vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in...

Via Benzinga

US FDA Approves GSK’s AREXVY, the World’s First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults

May 03, 2023

From GSK plc

Via Business Wire

GSK Stock Jumps After Beating Pfizer, Moderna To The RSV Vaccine Finish Line ↗

May 03, 2023

GSK won FDA approval for the first-ever RSV vaccine for older adults.

Via Investor's Business Daily

KVUE Stock: Should You Buy Into the Kenvue IPO? ↗

May 03, 2023

KVUE stock will be a dividend stock with an initial yield of 3.5%, with slow growth and lower margins than JNJ's drug business.

Via InvestorPlace

Pharma Giant Pfizer To Start Selling Haleon Stake Within Months, CFO Says ↗

May 03, 2023

Pfizer Inc (NYSE: PFE) is reportedly looking to start selling its stake in Haleon plc (NYSE: HLN).

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)

May 01, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review ↗

April 28, 2023

Microsoft, Meta, Cloudflare and Crocs were among the many big movers.

Via Investor's Business Daily

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

44 45 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.